Krishna Institute of Medical Sciences (KIMS) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
6 Aug, 2026Executive summary
Q1 FY27 revenue reached INR 1,196 crore (₹11,795 Mn), up 36.1% year-on-year and 10.3% quarter-on-quarter, with strong operational growth and expanded capacity.
EBITDA grew 20.1% year-on-year to INR 240 crore (₹2,398 Mn), with margin at 20.1%.
PAT was INR 37 crore (₹374 Mn), down 56% year-on-year but up 13% quarter-on-quarter, impacted by higher costs and statutory changes.
Significant expansion with 787 beds added in Kondapur and 208 beds in Palakkad during Q1 FY27.
Unaudited standalone and consolidated financial results for Q1 FY27 were approved by the Board, with auditors expressing unmodified review opinions.
Financial highlights
Consolidated revenue from operations at INR 1,180 crore (₹11,795 Mn), up 35.3% year-on-year and 9.8% quarter-on-quarter.
EBITDA: ₹2,398 Mn (20.1% margin), up 20.1% YoY and 10.9% QoQ.
PAT: ₹374 Mn, down 56% YoY but up 13% QoQ.
ARPOB rose 9.7% YoY to ₹47,200; occupancy at 49%.
Cash and cash equivalents stood at INR 505 crore as of June 30, 2026.
Outlook and guidance
Focus on ramping up new hospitals, especially Kondapur and upcoming Thrissur unit, and expanding bed capacity with 1,300+ beds planned.
Kerala cluster expected to stabilize at 20%-22% EBITDA margin over 2-3 years.
Telangana cluster occupancy targeted to reach 70% in 3-4 years, with EBITDA margins of 30%-35%.
Board approved raising up to Rs 6,000 million via convertible warrants to promoters, convertible within 18 months.
Board approved advancing loans and guarantees up to Rs 650 crore to subsidiaries, subject to shareholder approval.
Latest events from Krishna Institute of Medical Sciences
- FY26 revenue up 28.6%, but margins fell due to expansion and labor code expenses.KIMS
Q4 25/26 - Q3 FY26 revenue up 29.2% YoY, PAT down 43.9%, with expansion and major subsidiary investment.KIMS
Q3 25/26 - Q2 FY26 revenue up 23.3% YoY, but EBITDA margin and PAT declined; expansion and mergers ongoing.KIMS
Q2 25/26 - Q1 FY25 delivered strong revenue, profit, and margin growth, with major expansion and acquisitions.KIMS
Q1 24/25 - Strong revenue, EBITDA, and profit growth, major acquisition, and margin expansion achieved.KIMS
Q2 24/25 - Strong YoY revenue and EBITDA growth, ongoing expansion, and robust clinical milestones.KIMS
Q3 24/25 - Strong FY25 growth with margin expansion, acquisitions, and new hospital launches.KIMS
Q4 24/25 - Revenue up 26.8% YoY to INR 879 crore, EBITDA margin at 22.7%, expansion ongoing.KIMS
Q1 25/26